Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB 54828-801 Rollover Study of Pemigatinib
2023-503406-36-00Phase 2Completed
- Sponsor
- Incyte
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in cancer, sponsored by Incyte. Primary endpoint: Safety: frequency and nature of adverse events. Started Jun 2023; status: completed.
02
Drugs
pemigatinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2023-503406-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503406-36-00.